Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: dependent on RVX?

posted on Apr 03, 2018 11:30AM

Noretreat,

Zenith has ongoing mCRPC trials and other planned oncology clinical trials. Of course, funding is a big question. But Zenith can be successful with or without Resverlogix/apabetalone. Do yourself a favor and read the most recent Zenith MD&A and review the slide deck from BIO-Europe. Both from last month.